Thromboxane A2 activates YAP/TAZ protein to induce vascular smooth muscle cell proliferation and migration

Journal of Biological Chemistry

Volumn 291, Issue 36, 2016, Pages 18947-18958

  Feng, Xu ^a   Liu, Peng ^a   Zhou, Xin ^a   Li, Meng Tian ^a   Li, Fu Long ^a   Wang, Zhen ^a   Meng, Zhipeng ^b   Sun, Yi Ping ^a   Yu, Ying ^c   Xiong, Yue ^a,d   Yuan, Hai Xin ^a   Guan, Kun Liang ^a,b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; MUSCLE; PROTEINS;

ACTIN CYTOSKELETON; CARDIO-VASCULAR DISEASE; DNA SYNTHESISS; MULTIPLE CELLS; SIGNALING PATHWAYS; THERAPEUTIC TARGETS; VASCULAR INJURY; VASCULAR SMOOTH MUSCLE CELLS;

CELLS;

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 (3 HYDROXY 4 PHENYL 1 PENTEN 1 YL) 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACTIN; DNA; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; RHO KINASE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; 7-(3-(3-HYDROXY-4-(4'-IODOPHENOXY)-1-BUTENYL)-7-OXABICYCLO(2.2.1)HEPTAN-2-YL)-5-HEPTENOIC ACID; FUSED HETEROCYCLIC RINGS; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; UNSATURATED FATTY ACID; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ACTIN FILAMENT; ARTICLE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; CELL MOTION; CYTOLOGY; GENETICS; HELA CELL LINE; METABOLISM; PHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL MOVEMENT; CELL PROLIFERATION; FATTY ACIDS, UNSATURATED; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; HELA CELLS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHOPROTEINS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SIGNAL TRANSDUCTION; THROMBOXANE A2; TRANSCRIPTION FACTORS;

EID: 84984920689     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.739722     Document Type: Article

References (60)

1. Hamberg, M., Svensson, J., and Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U. S. A. 72, 2994-2998
2. Ting, H. J., Murad, J. P., Espinosa, E. V., and Khasawneh, F. T. (2012) Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting. J. Cardiovasc. Pharmacol. Ther. 17, 248-259
3. Braden, G. A., Knapp, H. R., and FitzGerald, G. A. (1991) Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 84, 679-685
4. Byrne, A., Moran, N., Maher, M., Walsh, N., Crean, P., and Fitzgerald, D. J. (1997) Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. 17, 3224-3229
5. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D. J. (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 840-845
6. Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., and FitzGerald, G. A. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541
7. Belton, O. A., Duffy, A., Toomey, S., and Fitzgerald, D. J. (2003) Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108, 3017-3023
8. Praticò, D., Cyrus, T., Li, H., and FitzGerald, G. A. (2000) Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96, 3823-3826
9. Yamagami, S., Miyauchi, K., Kimura, T., Goh, Y., Daida, H., and Yamaguchi, H. (1999) Effects of the thromboxane A2 receptor antagonist on platelet deposition and intimal hyperplasia after balloon injury. Jpn. Heart J. 40, 791-802
10. Inoue, T., and Node, K. (2009) Molecular basis of restenosis and novel issues of drug-eluting stents. Circ. J. 73, 615-621
11. Nakahata, N. (2008) Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 118, 18-35
12. Montuschi, P., Barnes, P. J., and Roberts, L. J., 2nd. (2004) Isoprostanes: markers and mediators of oxidative stress. FASEBJ. 18, 1791-1800
13. Gluais, P., Lonchampt, M., Morrow, J. D., Vanhoutte, P. M., and Feletou, M. (2005) Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br. J. Pharmacol. 146, 834-845
14. Audoly, L. P., Rocca, B., Fabre, J. E., Koller, B. H., Thomas, D., Loeb, A. L., Coffman, T. M., and FitzGerald, G. A. (2000) Cardiovascular responses to the isoprostanes iPF (2α)-III and iPE (2)-III are mediated via the thromboxane A (2) receptor in vivo. Circulation 101, 2833-2840
15. Ishimitsu, T., Uehara, Y., Ishii, M., Ikeda, T., Matsuoka, H., and Sugimoto, T. (1988) Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension 12, 46-51
16. Ishimitsu, T., Uehara, Y., Ishii, M., and Sugimoto, T. (1988) Enhanced generation of vascular thromboxane A2 in spontaneously hypertensive rats and its role in the rapid proliferation of vascular smooth muscle cells. Am. J. Hypertens. 1, 38S-40S
17. Hanasaki, K., Nakano, T., and Arita, H. (1990) Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells. Biochem. Pharmacol. 40, 2535-2542
18. Pakala, R., Willerson, J. T., and Benedict, C. R. (1997) Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96, 2280-2286
19. Pakala, R. (2004) Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc. Radiat. Med. 5, 20-26
20. Yokota, T., Shiraishi, R., Aida, T., Iwai, K., Liu, N. M., Yokoyama, U., and Minamisawa, S. (2014) Thromboxane A (2) receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation. PLoS ONE 9, e94895
21. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801
22. Cayatte, A. J., Du, Y., Oliver-Krasinski, J., Lavielle, G., Verbeuren, T. J., and Cohen, R. A. (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 1724-1728
23. Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., Katagiri, H., Majima, M., Yokode, M., Kita, T., and Narumiya, S. (2004) Roles of thromboxane A (2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114, 784-794
24. Egan, K. M., Wang, M., Fries, S., Lucitt, M. B., Zukas, A. M., Puré, E., Lawson, J. A., and FitzGerald, G. A. (2005) Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111, 334-342
25. Yu, F. X., Zhao, B., and Guan, K. L. (2015) Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811-828
26. Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H. W., Mo, J.-S., Lu, W., Lu, S., Flores, F., Yu, F.-X., Halder, G., and Guan, K.-L. (2015) MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 6, 8357
27. Zheng, Y., Wang, W., Liu, B., Deng, H., Uster, E., and Pan, D. (2015) Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase cascade. Dev. Cell 34, 642-655
28. Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., and Pan, D. (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133
29. Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., Zheng, P., Ye, K., Chinnaiyan, A., Halder, G., Lai, Z. C, and Guan, K. L. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761
30. Lei, Q. Y., Zhang, H., Zhao, B., Zha, Z. Y., Bai, F., Pei, X. H., Zhao, S., Xiong, Y., and Guan, K. L. (2008) TAZ promotes cell proliferation and epithelialmesenchymal transition and is inhibited by the Hippo pathway. Mol. Cell. Biol. 28, 2426-2436
31. Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C. Y., Chinnaiyan, A. M., Lai, Z. C, and Guan, K. L. (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962-1971
32. Zhao, B., Li, L., Tumaneng, K., Wang, C. Y., and Guan, K. L. (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP. Genes Dev. 24, 72-85
33. Harvey, K. F., Zhang, X., and Thomas, D. M. (2013) The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257
34. Miller, E., Yang, J., DeRan, M., Wu, C., Su, A. I., Bonamy, G. M., Liu, J., Peters, E. C, and Wu, X. (2012) Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 19, 955-962
35. Mo, J. S., Yu, F. X., Gong, R., Brown, J. H., and Guan, K. L. (2012) Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 26, 2138-2143
36. Yu, F. X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., Fu, X. D., Mills, G. B., and Guan, K. L. (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791
37. Wennmann, D. O., Vollenbröker, B., Eckart, A. K., Bonse, J., Erdmann, F., Wolters, D. A., Schenk, L. K., Schulze, U., Kremerskothen, J., Weide, T., and Pavenstädt, H. (2014) The Hippo pathway is controlled by angiotensin II signaling and its reactivation induces apoptosis in podocytes. Cell Death Dis. 5, e1519
38. Zhou, X., Wang, S., Wang, Z., Feng, X., Liu, P., Lv, X. B., Li, F., Yu, F. X., Sun, Y., Yuan, H., Zhu, H., Xiong, Y., Lei, Q. Y., and Guan, K. L. (2015) Estrogen regulates Hippo signaling via GPER in breast cancer. J. Clin. Invest. 125, 2123-2135
39. Wang, X., Hu, G., Gao, X., Wang, Y., Zhang, W., Harmon, E. Y., Zhi, X., Xu, Z., Lennartz, M. R., Barroso, M., Trebak, M., Chen, C, and Zhou, J. (2012) The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation. Arterioscler. Thromb. Vasc. Biol. 32, 2662-2669
40. Xie, C., Guo, Y., Zhu, T., Zhang, J., Ma, P. X., and Chen, Y. E. (2012) Yap1 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. J. Biol. Chem. 287, 14598-14605
41. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., Elvassore, N., and Piccolo, S. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183
42. Fernández, B. G., Gaspar, P., Brás-Pereira, C., Jezowska, B., Rebelo, S. R., and Janody, F. (2011) Actin-capping protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development 138, 2337-2346
43. Rauskolb, C., Pan, G., Reddy, B. V., Oh, H., and Irvine, K. D. (2011) Zyxin links fat signaling to the hippo pathway. PLoS Biol. 9, e1000624
44. Sansores-Garcia, L., Bossuyt, W., Wada, K., Yonemura, S., Tao, C., Sasaki, H., and Halder, G. (2011) Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 30, 2325-2335
45. Zhao, B., Li, L., Wang, L., Wang, C. Y., Yu, J., and Guan, K. L. (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54-68
46. Chan, E. H., Nousiainen, M., Chalamalasetty, R. B., Schäfer, A., Nigg, E. A., and Silljé, H. H. (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24, 2076-2086
47. Marx, S. O., Totary-Jain, H., and Marks, A. R. (2011) Vascular smooth muscle cell proliferationinrestenosis. Circ. Cardiovasc. Interv. 4, 104-111
48. Ricciotti, E., and FitzGerald, G. A. (2011) Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986-1000
49. Smyth, E. M., Grosser, T., Wang, M., Yu, Y., and FitzGerald, G. A. (2009) Prostanoids in health and disease. J. Lipid Res. 50, S423-S428
50. Fetalvero, K. M., Shyu, M., Nomikos, A. P., Chiu, Y. F., Wagner, R. J., Powell, R. J., Hwa, J., and Martin, K. A. (2006) The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am. J. Physiol. Heart Circ. Physiol. 290, H1337-H1346
51. Yu, F. X., Zhang, Y., Park, H. W., Jewell, J. L., Chen, Q., Deng, Y., Pan, D., Taylor, S. S., Lai, Z. C., and Guan, K. L. (2013) Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 27, 1223-1232
52. Bauer, J., Ripperger, A., Frantz, S., Ergün, S., Schwedhelm, E., and Benndorf, R. A. (2014) Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br. J. Pharmacol. 171, 3115-3131
53. Peterson, M. B., Machaj, V., Block, P. C., Palacios, I., Philbin, D., and Watkins, W. D. (1986) Thromboxane release during percutaneous transluminal coronary angioplasty. Am. Heart J. 111, 1-6
54. Cicha, I., Yilmaz, A., Klein, M., Raithel, D., Brigstock, D. R., Daniel, W. G., Goppelt-Struebe, M., and Garlichs, C. D. (2005) Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler. Thromb. Vasc. Biol. 25, 1008-1013
55. Matsumae, H., Yoshida, Y., Ono, K., Togi, K., Inoue, K., Furukawa, Y., Nakashima, Y., Kojima, Y., Nobuyoshi, M., Kita, T., and Tanaka, M. (2008) CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Arterioscler. Thromb. Vasc. Biol. 28, 1077-1083
56. Lee, H. Y., Chung, J. W., Youn, S. W., Kim, J. Y., Park, K. W., Koo, B. K., Oh, B. H., Park, Y. B., Chaqour, B., Walsh, K., and Kim, H. S. (2007) Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 100, 372-380
57. Michels, S., and Schmidt-Erfurth, U. (2001) Photodynamic therapy with verteporfin: a new treatment in ophthalmology. Semin. Ophthalmol. 16, 201-206
58. Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S. J., Anders, R. A., Liu, J. O., and Pan, D. (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300-1305
59. Lv, X. B., Liu, C. Y., Wang, Z., Sun, Y. P., Xiong, Y., Lei, Q. Y., and Guan, K. L. (2015) PARD3 induces TAZ activation and cell growth by promoting LATS1 and PP1 interaction. EMBO Rep. 16, 975-985
60. Ray, J. L., Leach, R., Herbert, J. M., and Benson, M. (2001) Isolation of vascular smooth muscle cells from asingle murine aorta. Methods Cell Sci. 23, 185-188